Infectious adverse events in patients with atopic dermatitis treated with baricitinib.

Baricitinib is a JAK1-2 inhibitor recently approved in Europe and Japan for the treatment of moderate-to-severe atopic dermatitis in adult patients at doses of 2 and 4 mg daily. The aim of this article is to discuss the safety profile of baricitinib in atopic dermatitis using data from clinical trials and the supporting literature, with a focus on infectious adverse events. An integrated analysis of safety data from eight clinical trials described infections as the most frequent treatment-emergent adverse events, mainly of mild-to-moderate severity, notably upper respiratory tract infections and herpes simplex exacerbations. Real-world data are still limited and will contribute to precisely profile the patients that might benefit from this treatment.

Baricitinib is a drug taken by mouth, currently approved for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy, a medication that is designed to be absorbed into the bloodstream and work throughout the body. Baricitinib is available as 2- and 4-mg tablets and has been shown to improve the cutaneous manifestations, such as dry and cracked skin, redness and symptoms of atopic dermatitis, especially itchiness. Baricitinib is generally well tolerated. The most common adverse events that have emerged from clinical trials include headache, nausea and high cholesterol. Another reported side effect is an increased risk of infections, mainly of mild-to-moderate severity, especially upper respiratory tract infections such as nasopharyngitis (inflammation of the nose and throat) and reactivation of herpes zoster, a virus that causes a painful rash on one side of the body, and herpes simplex, which causes clustered blisters usually on the lips or genitals. There is still a lack of data from real-world experience, which will be important for the development of a more precise profile of patients who may benefit from this treatment.

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.

Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of moderate-to-severe psoriasis. Based on published literature and their clinical experience a steering committee drafted 17 statements covering 7 domains specific to the treatment of moderate-to-severe psoriasis with brodalumab. A panel of 32 Italian dermatologists indicated their level of agreement using a 5-point Likert scale (from 1 = "strongly disagree" to 5 = "strongly agree") using an online modified Delphi method. After the first round of voting (32 participants), positive consensus was reached for 15/17 (88.2%) of the proposed statements. Following a face-to-face virtual meeting, the steering committee decided that 5 statements would form "main principles" and 10 statements formed the final list. After a second round of voting, consensus was reached in 4/5 (80%) of the main principles and 8/10 (80%) for consensus statements. The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis.